Peer-Reviewed Publications

      Aerosol flow in the Vitrocell 24/48 exposure system: Flow mixing and aerosol coalescence

      Kuczaj, A. K.; Nordlund, M.; Jayaraju, S.; Komen, E.; Krebs, T.; Peitsch, M. C.; Hoeng, J.
      Published
      Sep 1, 2016
      DOI
      10.1089/aivt.2016.0009
      Link to publication
      Topic
      Summary

      In vitro exposure systems are increasingly used in modern toxicology assessment studies. An understanding of the functioning of these complex systems and their characterization ensures well-controlled delivery of substances to cell cultures and reliable biological response of cells to the given external conditions. In this work, we present the flow-mixing efficiency of the dilution unit in the Vitrocell® 24/48 (VC24/48) exposure system, together with the role of thermal coalescence. We adopted a computational fluid dynamics approach with integrated aerosol dynamics to analyze the dilution system using high-resolution simulations. We performed simulations for three total flow rates through the system: 3, 6, and 12 L/min, to investigate the influence of turbulent mixing and thermal coalescence on the aerosol characteristics. We found that for all simulated flow rates, instantaneous and localized turbulent mixing is induced by the two opposing dilution jets. We found the aerosol to be uniformly mixed and the flow to be laminarized upstream of the location of the first aerosol sampling trumpet. In summary, the design of the double-tee junction, serving as the dilution unit of the VC24/48 system, guarantees efficient and localized mixing/dilution of the aerosol, while still delivering laminar flow toward deposition wells, when operated under these high flow-rate conditions. In addition, we showed that thermal coalescence effects do not influence the aerosol droplet size distribution during the dilution process for the studied simulation conditions.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.